Alberta Diabetes Institute, 2-004 Li Ka Shing Centre for Health Research Innovation 8602 (Site 124103)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Type 1 diabetes

Running trials

• Active, not recruiting

  Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

  NCT04598893· Phase 3· Provention Bio, a Sanofi Company· Source